hn.today

Show HN: Why Zero to One's Thesis Falls Short with Healthcare

davidngo1562.substack.com3 points0 comments
Screenshot of Show HN: Why Zero to One's Thesis Falls Short with Healthcare

The central argument is that healthcare innovations cannot be judged by product quality or market size alone: founders must understand who pays, whether that buyer saves or earns money, and whether patients will actually use the product. In ordinary consumer markets, the user and buyer are usually the same person. Healthcare often separates them, so a product can be valuable to patients yet unattractive to insurers or providers. This, the author argues, exposes a blind spot in the startup principles in Zero to One, which emphasize breakthroughs, durable markets, strong teams, and scalable distribution without sufficiently examining the buyer’s incentives and the user experience.

Akili’s ADHD treatment game EndeavorRx illustrates the mismatch. Despite FDA approval and a potential alternative to medication, insurers faced ongoing costs, uncertain lasting benefits, and a product patients often found tedious to use. Its consumer version also struggled, and Akili’s value collapsed before its acquisition. Cognoa’s autism-diagnosis app Canvas Dx offers a contrast: delayed diagnoses can generate costly care, while the app is a one-time assessment that can shorten waits and reduce insurer spending. Its standardized process may also limit waste and widen access. Insurers and public programs have begun covering it, and Cognoa’s partnership with Catalight could extend its reach. The comparison suggests healthcare products need both a clear financial case for whoever pays and a workable experience for whoever uses them.

Read on davidngo1562.substack.com0 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Startups

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.